Vadadustat: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 448 patientsc19early.org

Vadadustat for COVID-19

Serious outcome risk
Vadadustat
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−3%
Mortality (1)−3%
RCTs (1)−3%
Late (1)−3%
00.511.5+
← Vadadustat
reduces riskIncreased
risk →
c19early.org
October 2026

Vadadustat COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bobrow (DB RCT)−3%1.03 · 0.56–1.89death19/22119/227VSTAT
Late treatment−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.94
All studies−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9400.511.52+
Rotate screen for more detailsIncrease width for more details
← Vadadustat
reduces riskVadadustat
increases risk →
c19early.org
October 2026

Vadadustat COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bobrow (DB RCT)−3%1.03 · 0.56–1.8919/22119/227VSTAT
Late treatment−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.94
All studies−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9400.511.52+
Rotate screen for more detailsIncrease width for more details
← Vadadustat
reduces riskVadadustat
increases risk →
c19early.org
October 2026

Vadadustat COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bobrow (DB RCT)−3%1.03 · 0.56–1.89death19/22119/227VSTAT
Late treatment−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.94
All studies−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9400.511.52+
Rotate screen for more detailsIncrease width for more details
← Vadadustat
reduces riskVadadustat
increases risk →
c19early.org
October 2026

Vadadustat COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bobrow (DB RCT)8%0.92 · 0.68–1.23no recov.58/21466/223VSTAT
Late treatment8%0.92 · 0.68–1.2358/21466/2238% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies8%0.92 · 0.68–1.2358/21466/2238% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Vadadustat
reduces riskVadadustat
increases risk →
c19early.org
October 2026

Vadadustat COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bobrow (DB RCT)−3%1.03 · 0.56–1.89death19/22119/227VSTAT
Late treatment−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.94
All studies−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9400.511.52+
Rotate screen for more detailsIncrease width for more details
← Vadadustat
reduces riskVadadustat
increases risk →
c19early.org
October 2026

Vadadustat COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bobrow (DB RCT)−3%1.03 · 0.56–1.8919/22119/227VSTAT
Late treatment−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.94
All studies−3%1.03 · 0.56–1.8919/22119/2273% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9400.511.52+
Rotate screen for more detailsIncrease width for more details
← Vadadustat
reduces riskVadadustat
increases risk →